What patent covers Crysvita (burosumab) and what does “spr caracterization” mean?
“Crysvita” is the brand name for burosumab, an anti-FGF23 antibody used for certain rare bone diseases. However, the phrase “spr caracterization” is not a standard, widely used term in public patent databases for Crysvita. It may refer to:
- a patent document section about “characterization” studies (e.g., binding, functional assays, in vitro/in vivo characterization), or
- a specific classification/keyword used by a local database (“SPR”) in how documents are tagged or filtered.
To identify the exact patent, you’d need either the patent number/publication number, the assignee (company), or the exact wording you saw next to “spr caracterization.”
Which patents are typically involved in Crysvita (burosumab)?
Crysvita-related patent families usually fall into a few categories, such as:
- the antibody molecule (sequence/structure and engineered variants),
- production methods and formulations,
- diagnostic/biomarker work tied to treatment selection or monitoring,
- clinical use claims (specific diseases, dosing regimens, patient subsets).
Public sources often show multiple overlapping filings for different parts of the program, so “the” Crysvita patent can mean different things depending on whether you’re looking for the active ingredient, a formulation, or a method of treatment.
How can you find the exact “spr caracterization” patent entry?
If you have any of the following, the patent can be pinpointed quickly:
- the patent number (e.g., US..., EP..., WO...)
- the document title or a snippet containing “caracterization” and “spr”
- the applicant/assignee name shown in the record
- the country or database you searched (Google Patents, Espacenet, national registry)
If you paste the exact text from the search result (including “spr caracterization”), I can map it to the most likely patent document and explain what the “characterization” part covers.
How long does Crysvita patent protection usually last?
For biologics, patent term timing depends on filing and whether patents are granted in each jurisdiction, plus any patent-term adjustments or supplemental protection mechanisms that apply locally. Exact end dates require the specific patent publication(s) you’re referencing, not the product name alone.
Are there challenges or workarounds that affect Crysvita exclusivity?
For biologics, exclusivity and “when generics/biosimilars can enter” depend on a mix of:
- patents on the antibody and its specific claimed features,
- patents on methods of use/dosing,
- data exclusivity/market exclusivity rules (jurisdiction-specific),
- regulatory pathways and whether a product is considered a biosimilar/bioequivalent.
Again, the key to answering precisely is which patent you mean by “spr caracterization.”
What I need from you to answer precisely
Send one of these and I’ll give you the exact patent and what it claims:
- the patent number/publication number you’re seeing, or
- the assignee name + the exact phrase surrounding “spr caracterization,” or
- a screenshot/text copy of the search result.
Sources: none used (the prompt didn’t include the actual “spr caracterization” patent text or a patent identifier).